B. Riley Securities Upgrades Mirati Therapeutics to Buy, Announces $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Kalpit Patel has upgraded Mirati Therapeutics (NASDAQ:MRTX) from Neutral to Buy and set a price target of $45.
August 09, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirati Therapeutics has been upgraded from Neutral to Buy by B. Riley Securities, with a new price target of $45.
The upgrade from Neutral to Buy by B. Riley Securities indicates a positive outlook for Mirati Therapeutics. The new price target of $45 suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100